Arvinas Inc (ARVN)vsModerna Inc (MRNA)
ARVN
Arvinas Inc
$8.45
-2.99%
HEALTHCARE · Cap: $545.20M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 604% more annual revenue ($2.23B vs $316.70M). ARVN leads profitability with a 2.9% profit margin vs -141.4%. ARVN earns a higher WallStSmart Score of 56/100 (C).
ARVN
Buy56
out of 100
Grade: C
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARVN.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 66.4%
Revenue surging 1015.0% year-over-year
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 1.6% — below average capital efficiency
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARVN
The strongest argument for ARVN centers on Price/Book, Operating Margin, Revenue Growth. Revenue growth of 1015.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ARVN
The primary concerns for ARVN are P/E Ratio, EPS Growth, Market Cap. Thin 2.9% margins leave little buffer for downturns.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ARVN profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
ARVN carries more volatility with a beta of 1.76 — expect wider price swings.
ARVN is growing revenue faster at 1015.0% — sustainability is the question.
ARVN generates stronger free cash flow (-49M), providing more financial flexibility.
Bottom Line
ARVN scores higher overall (56/100 vs 21/100) and 1015.0% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arvinas Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?